Rech. f.与Esfand作为根除治疗的辅助疗法：一项随机对照试验。
Rech. f. & Esfand as adjunctive therapy for eradication: a randomized controlled trial.
作者信息
Vaziri Nima, Dehghannoudeh Gholamreza, Sharififar Fariba, Dabaghzadeh Fatemeh, Sarafzadeh Farhad, Ahmadi Bizhan
机构信息
Herbal and Traditional Medicines Research Center, Kerman University of Medical Sciences, Kerman 761, Iran.
Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 761, Iran.
出版信息
J Tradit Chin Med. 2025 Apr;45(2):437-442. doi: 10.19852/j.cnki.jtcm.2025.02.009.
OBJECTIVE
To evaluate the effect of this plant as adjunctive therapy on () eradication.
METHODS
The plant capsules were prepared and their physicochemical properties were assessed. In this clinical trial, 99 patients with infection were randomized to receive Rech. f. & Esfand () or placebo capsules for two weeks. All the patients in both groups received clarithromycin-based triple therapy. Both intention to treat and per protocol analyses were performed. Eradication rates, treatment side effects, and medication compliance were evaluated in both groups.
RESULTS
H. pylori eradication rate of all the randomized participants was 59.59%. The eradication rate of was significantly higher in group compared with that in the placebo group for per protocol analysis (84.62%, = 0.026) but not for intention to treat one (65.31%, 0.252). There were no significant differences between the two groups regarding the frequencies of the medications side effects and the patients with poor compliance.
CONCLUSION
The use of as adjunctive therapy to 14-day clarithromycin-based triple therapy might improve eradication rate.
目的
评估这种植物作为辅助治疗对（）根除的效果。
方法
制备植物胶囊并评估其理化性质。在这项临床试验中，99例感染（）的患者被随机分为接受（）或安慰剂胶囊治疗两周。两组所有患者均接受以克拉霉素为基础的三联疗法。进行了意向性分析和符合方案分析。评估两组的根除率、治疗副作用和用药依从性。
结果
所有随机参与者的幽门螺杆菌根除率为59.59%。在符合方案分析中，（）组的根除率显著高于安慰剂组（84.62%，=0.026），但在意向性分析中并非如此（65.31%，0.252）。两组在药物副作用频率和依从性差的患者方面没有显著差异。
结论
将（）作为基于克拉霉素的14天三联疗法的辅助治疗可能会提高根除率。
Zotero 插件